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Abstract
Pharmacological tools for chronic visceral pain management are still limited and inadequate. A3 adenosine receptor (A3AR) agonists
are effective in different models of persistent pain. Recently, their activity has been related to the block of N-type voltage-gated Ca21
channels (Cav2.2) in dorsal root ganglia (DRG) neurons. The present work aimed to evaluate the efficacy of A3AR agonists in reducing
postinflammatory visceral hypersensitivity in both male and female rats. Colitis was induced by the intracolonic instillation of 2,4-
dinitrobenzenesulfonic acid (DNBS; 30 mg in 0.25 mL 50% EtOH). Visceral hypersensitivity was assessed by measuring the
visceromotor response and the abdominal withdrawal reflex to colorectal distension. The effects of A3AR agonists (MRS5980 and
Cl-IB-MECA) were evaluated over time after DNBS injection and compared to that of the selective Cav2.2 blocker PD173212, and
the clinically used drug linaclotide. A3AR agonists significantly reduced DNBS-evoked visceral pain both in the postinflammatory (14
and 21 days after DNBS injection) and persistence (28 and 35 days after DNBS) phases. Efficacy was comparable to effects induced
by linaclotide. PD173212 fully reduced abdominal hypersensitivity to control values, highlighting the role of Cav2.2. The effects of
MRS5980 and Cl-IB-MECA were completely abolished by the selective A3AR antagonist MRS1523. Furthermore, patch-clamp
recordings showed that A3AR agonists inhibited Cav2.2 in dorsal root ganglia neurons isolated from either control or DNBS-treated
rats. The effect on Ca21 current was PD173212-sensitive and prevented by MRS1523. A3AR agonists are effective in relieving
visceral hypersensitivity induced by DNBS, suggesting a potential therapeutic role against abdominal pain.
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1. Introduction
Visceral pain management is a major clinical problem, because of
the lack of effective and safe drugs.11 Abdominal pain is the most
common form of visceral hypersensitivity and is often the result of
inflammatory bowel diseases (IBDs).14,51,84,85 The poor correla-
tions between reported abdominal pain intensity and IBD activity
raise close similarities with the irritable bowel syndrome (IBS),
a symptom-based clinical condition defined by the presence of
persistent abdominal pain and altered bowel habits, in the
absence of any other disease able to account for these
symptoms.24,35,51,58,84,85 Frequently, IBS results from a previous
intestinal damage caused by severe infections or prolonged
inflammatory processes.24,83 In the inflamed gut, there is
breakdown of intestinal barrier function, abnormal secretion,
changes in the patterns of motility, and altered visceral sensation,
which altogether contribute to generation of symptoms (di-
arrhoea, cramping, and pain). Pain, in particular, persists beyond
the relief of inflammation, thus revealing a peculiar kind of chronic
hypersensitivity thought to be due to inflammatory, immune, and
neuropathic mechanisms.9,26,40,53,86 Currently, the most effica-
cious therapies against visceral hypersensitivity are mainly
directed toward treating bowel dysfunction, whereas drugs able
to directly target the associated pain are still unsatisfactory.11
The neuromodulator adenosine exerts potent and long-lasting
pain suppression in preclinical models as well as in human
studies.105 Moreover, adenosinergic signalling is known to
modulate intestinal functionality.2–4 For decades, it was thought
that the analgesic effects of adenosine were mediated by A1
adenosine receptor (A1AR) activation,
8,54,65,77,105 but research
efforts over the past several years have also implicated a key role
for the A3AR subtype.
43,75 For example, A3AR agonists are able
to block the development of trauma- and chemotherapeutic-
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induced neuropathic pain17,42 and are also effective in reducing
inflammatory and cancer-related pain.50,93,100,101 Recently, we
found that selective A3AR stimulation inhibits the opening of N-
type voltage-gated Ca21 channels (Cav2.2) and decreases the
electrically evoked excitation of isolated rat dorsal root ganglia
(DRG) neurons. This mechanism could explain the antihyper-
algesic effect of A3AR agonists across different models.
19
Therapeutic targeting of A1AR has been limited to severe
cardiovascular side effects; by contrast, A3AR agonists are
already in advanced clinical trials for different indications with
a good safety profile.29,80
The aims of this study were to: (1) evaluate the efficacy of
selective A3AR agonists in postinflammatory visceral hypersen-
sitivity induced in male and female rats by the intrarectal
administration of 2,4-dinitrobenzenesulfonic acid (DNBS); (2)
investigate the electrophysiological effects of selective A3AR
stimulation on DRG neurons isolated from control and DNBS-
treated animals.
2. Materials and methods
An extensive description of materials and methods has been
reported in the supplemental digital content (available at http://
links.lww.com/PAIN/B10).
2.1. Animals
We used male and female Sprague-Dawley rats (Envigo, Varese,
Italy) weighing approximately 220 to 250 g at the beginning of the
experimental procedure. All animal manipulations were con-
ducted according to the Directive 2010/63/EU of the European
Parliament and of the European Union Council (September 22,
2010) on the protection of animals used for scientific purposes.
The ethical policy of the University of Florence complies with the
Guide for the Care and Use of Laboratory Animals of the US
National Institutes of Health (NIH Publication No. 85-23, revised
1996; University of Florence assurance number: A5278-01).
Formal approval to conduct the described experiments was
obtained from the Animal Subjects ReviewBoard of the University
of Florence. Experiments involving animals have been reported
according to ARRIVE guidelines.57 Gastrointestinal motility
assays (GI) were conducted using Sprague-Dawley male rats
(Envigo, 250-350 g) in accordance with the University of Arizona
Institutional Animal Care and Use Committee (approval 06-110).
Experiments were performed on male rats when not otherwise
stated.
2.2. Determination of female estrous cycle phases
Estrous cycle was assessed in rats by analysing rat vaginal
smears as previously described.39 This screening was performed
before the behavioral test; tests were selectively performed in
female rats in estrous/proestrous phase to avoid sensitive
difference related to the estrous cycle. Moreover, in most studies,
this phase is reported to be related to the highest pain
sensitivity,45,46,59,60,74 therefore suitable for studying pain-
relieving compounds.
2.3. Induction of colitis
Colitiswas inducedusing themethoddescribedpreviously by Fornai
et al.30 with minor changes. In brief, during a short period of
anaesthesia with isoflurane (2%), 30mg of DNBS in 0.25mL of 50%
ethanol was administered intrarectally through a polyethylene PE-60
catheter inserted 8 cm proximal to the anus. Control rats received
0.25 mL of saline solution. Subsequent experimental procedures
began 14 days after DNBS administration to allow for recovery from
the initial colonic inflammation.
2.4. Assessment of visceral sensitivity by visceromotor
response and abdominal withdrawal reflex
The visceromotor response (VMR) to colorectal distension (CRD)
was used as an objective measure of visceral sensitivity.
Visceromotor response assessment was conducted in animals
under light anaesthesia (2% isoflurane) 14 and 21 days after
DNBS administration. The amplitude of the abdominal contrac-
tion consequent to colorectal stimulation (a balloon inflated with
0.5, 1, 2, and 3 mL referred to as distension volume) was
quantified by electromyography recordings as reported by Parisio
et al.64 Behavioural responses to CRD (0.5, 1, 2, and 3 mL
referred to as distension volume) were assessed through
abdominal withdrawal reflex (AWR) measurement in conscious
animals by using a semiquantitative score (0-4) as described
previously.16 Themeasurements were conducted 14, 21, 28, and
35 days after DNBS administration.
2.5. Upper gastrointestinal transit treatment and harvesting
All experiments were performed as previously described.66,76,95
Before experiment, rats were fasted for 12 hours, maintaining the
access to water ad libitum. After 15 minutes had elapsed, rats
were then given an oral gavage with fluorescein isothiocyanate
dextran (300 mL of 5 mg/mL 70 kDa FITC-dextran; Sigma, Milan,
Italy). Forty min after completing the gavage, rats were
anaesthetized with isoflurane and whole blood harvested through
cardiac puncture. After blood harvest, the upper portion of the
gastrointestinal tract was carefully removed, being cut proximally
at the pyloric sphincter and distally at the cecum. The intestine
was sectioned into 10 equal lengths, which were homogenized in
1 mL 1X PBS and then centrifugated. Fluorescence was
determined in the supernatants collected from intestinal lining
(10 mL) and content diluted into 90 mL 1X PBS; serum
fluorescence was determined after dilution of 10 mL serum into
40 mL 1X PBS using a ClarioStar (BMG Labtech, Milan, Italy) at
483 to 530 nm. Readings were then collected and prepared for
statistical analyses.
2.6. Drug administration
The selective A3 ARagonist, 2-chloro-N
6-(3-iodobenzyl)-adenosine-
59-N-methyluronamide (Cl-IB-MECA; Tocris Bioscience, Bristol,
United Kingdom), and the selective A3 receptor antagonist, 3-
propyl-6-ethyl-5-[(ethylthio)carbonyl]-2 phenyl-4-propyl-3-pyridine
carboxylate (MRS1523; Sigma-Aldrich, Milan, Italy), were dissolved
in 5% DMSO and 5% TWEEN 20 saline solution for in vivo
administration. The new, highly selective (10,000-fold vs each of the
other 3 receptor subtypes) A3AR agonist, MRS5980,
(1S,2R,3S,4R,5S)-4-(2-((5-chlorothiophen-2-yl)ethynyl)-6-(methyla-
mino)-9H-purin-9-yl)-2,3-dihydroxy-N-methylbicyclo[3.1.0]hexane-
1-carboxamide89 was dissolved in 5% DMSO saline solution for in
vivo administration. As already reported,50 the antiallodynic effects of
the A3AR agonists used in this work were lost in the A3AR knockout
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in vivo administration. Both the vehicle and the DNBS control
groups received an i.p. injection of the vehicle used for the
administration of the respective molecules. The acute in-
jection of the vehicles (5% DMSO or 5% DMSO1 5% TWEEN
20) did not alter visceral pain threshold and did not induce side
effects in the animals. The guanylate cyclase-C (GC-C)
agonist linaclotide (Allergan, Buckinghamshire, United King-
dom) was dissolved in water and orally administered 1 hour
before starting the behavioural tests.25 Cl-IB-MECA,
MRS5980, and PD173232 were administered i.p. 15 minutes
before the test. MRS1523 was administered i.p. 15 minutes
before Cl-IB-MECA and MRS5980. Gastrointestinal transit
study: the compound MRS5980 was dissolved in 5% DMSO,
and then suspended in saline. MRS5980 and vehicle were
administered through i.p. injection to all animals in study at 2.4
mmol·kg21 body weight (1 mL/kg injection volume). Seventy
kDa FITC-dextran (Sigma) was dosed by oral gavage at
a concentration of 5 mg/mL, 300 mL per rat. Additional
pharmacological characteristics of A3 AR agonists are shown
in the Supplemental material (available at http://links.lww.
com/PAIN/B10).
2.7. Cell cultures
Primary DRG neurons (related to colon-sensitive innervations:
T12, T13, L4, L5, L6, S1, S2) were isolated from vehicle- or
DNBS-treated (at 14th day) rats and cultured for 1 to 2 days
before being used for experiments as described.19
2.8. Electrophysiology
Whole-cell patch-clamp recordings were performed as pre-
viously described.19 Passive membrane properties of DRG
neurons isolated from control or DNBS-treated rats were
investigated under physiological-like conditions by using the
following K-gluconate- based pipette solution (mM): KGlu 130;
NaCl 4.8; KCl 10; MgCl2 2; CaCl2 1; Na2-ATP 2; Na2-GTP 0.3;
EGTA 3; HEPES 10 (pH 7.4 with KOH). Resting membrane
potential (Vm) wasmeasured immediately after seal breakthrough
by switching the amplifier to the current-clamp mode. The
calculated liquid junction potential for K-gluconate pipettes in our
experimental conditions was 15.0 mV, and Vm values reported in
the present research have been corrected accordingly.
Voltage-dependent Ca21 currents (VDCCs) were recorded by
using aCs1-based pipette solution having the following composition
(mM): CsCl (130); NaCl (4.8); KCl (10); MgCl2 (2); CaCl2 (1); Na2-ATP
(2); Na2-GTP (0.3); EGTA (3); and HEPES (10—pH 7.4 with CsOH).
The extracellular solution was (in mM): NaCl (147); CsCl (4); MgCl2
(1); and CaCl2 (5); HEPES (10); D-glucose (10); pH 7.4 with NaOH.
Tetrodotoxin (TTX; 1mM) and 5-(4-butoxy-3-chlorophenyl)-N-[[2-(4-
morpholinyl)-3-pyridinyl]methyl]-3-pyridinecarboxamide (A887826;
200 nM) were added to the extracellular solution to block TTX-
sensitive Nav1.1, 1.2, 1.3, 1.4, 1.6, 1.7 channels and TTX-resistant
Nav1.8, respectively. VDCC currents were evoked by a 0 mV step
depolarization (200 ms) once every 30 seconds to minimize Ca21
current run down. Peak Ca21 current (ICa peak) was measured as
the peak current amplitude reached during the first 50 ms of voltage
step. Steady-state Ca21 current (ICa st-state) was measured as the
averaged current amplitude measured between 160 and 190 ms of
voltage step. The current-to-voltage relationship (I-V plot) of Ca21
currents was obtained by eliciting 10 depolarizing voltage steps
(200-ms duration, 10-mV increments, 5-second interval) from 250
to150 mV starting from a holding potential (Vh) of265 mV.
Data were acquired with an Axopatch 200B amplifier (Axon
Instruments, San Jose,CA), low-pass filtered at 10 kHz, and stored
and analysed with pClamp 9.2 software (Axon Instruments).
Membrane resistance (Rm) andmembrane capacitance (Cm)were
routinely measured by fast hyperpolarizing voltage pulses (from
260 to 270 mV, 40-ms duration). Averaged currents were
normalized to cell capacitance and expressed as pA/pF.
Cell capacitance was used to estimate neuronal diameter by
assuming an approximated spherical cell shape according to the
calculated Cm for all biological membranes of 1 mF/cm2 and to
the equation of the sphere surface: A 5 4pr2.
The in vitro concentrations were chosen on the base of our
previous work: the A3AR agonists Cl-IB-MECA and MRS5980
were applied at 30 nM, a concentration able to produce maximal
inhibition of Ca21 currents in rat DRG neurons.19
2.9. Statistical analysis
Behavioural measurements were performed on 6 animals for
each treatment. All the experimental procedures were performed
by a researcher blind to the treatment. Results were expressed as
mean 6 SEM. The analysis of variance (ANOVA) of behavioural
data was performed by one-way ANOVA with Bonferroni’s
significant difference procedure used for post hoc comparisons.
Statistics of electrophysiological data was performed by Student
paired or unpaired t test or by one-way ANOVA followed by
Bonferroni’s post hoc test, as appropriate. P values of less than
0.05 were considered significant. Data were analyzed using the
“Origin 9” software (OriginLab, Northampton, MA). Data from
gastrointestinal transit measures were analyzed in GraphPad
Prism 7. Standard curves were fit using a nonlinear, hyperbolic
equation for individual plates. A two-way ANOVA with Tukey post
hoc test was performed using the variables of GI segment and
treatment. Serum samples were compared using an unpaired
t test. Data were considered statistically significant when P ,
0.05 to detect 20% difference with 80% power (necessary n-
values determined using G.Power3.1).
3. Results
3.1. A3AR agonists reduce colitis-induced visceral
hypersensitivity in rats
The visceromotor response and the abdominal withdrawal reflex
(VMR and AWR) to CRD were measured by using progressively
increasing balloon volumes as pressuring stimuli on the colon
(highest volume: 3 mL, to avoid tissue damage). Fourteen and 21
days after DNBS injection, both VMR and AWR were significantly
higher in comparison to controls (vehicle 1 vehicle) as shown,
respectively, in Figures 1A–B (day 14) and 1C–D (day 21). On day
14, the acute administration of MRS5980 (0.3, 1.2, and 2.4
mmol·kg21; i.p.) dose-dependently reduced the postinflammatory
visceral hypersensitivity induced by DNBS; the magnitude of the
reduction was similar for VMR and AWR. The highest dose (2.4
mmol·kg21) completely reversed the sensitivity alteration back to the
value of control rats. MRS5980 1.2 mmol·kg21 partially but
significantly reduced the response of the animals to CRD. The
lowest dose of MRS5980 (0.3 mmol·kg21) was ineffective in both
tests (Figs. 1A and B). On day 21, the effect of MRS5980 (0.3, 1.2,
and 2.4 mmol·kg21) was confirmed (VMR and AWR to CRD, Figs.
1C and D, respectively).
Figure 2A shows the result of the pretreatmentwith the selective
A3AR antagonist MRS1523
49 on the antihyperalgesic effect of
MRS5980 on day 14. MRS1523 (5 mmol kg21) completely
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abolished the pain-relieving effect of MRS5980 (2.4 mmol kg21)
confirming a A3AR mechanism of action. Furthermore, the pain-
relieving effect evokedbyA3ARstimulationwas confirmedby using
another selective A3ARagonist, Cl-IB-MECA.Onday 14, the acute
administration of Cl-IB-MECA dose-dependently relieved visceral
pain in DNBS-treated animals, reducing their VMR to the value of
controls (dosed at 1.2 mmol·kg21, Fig. 2B). The lowest dose of
0.3mmol·kg21 evoked aweaker effect only with the 2mL stimulus.
The Cl-IB-MECA (1.2mmol·kg21) effect was blocked byMRS1523
(5 mmol·kg21, Fig. 2B).
3.2. N-type voltage-gated Ca21 channel block relieves
colitis-induced visceral pain in rats
A3AR agonists have been recently reported to inhibit Cav2.2-
mediated currents in DRG neurons, thus suggesting a possible
mechanism for pain relief.19 To verify this hypothesis, we evaluated
the effect of acute administration of the selective N-type Cav2.2
blocker PD17321238 in our visceral pain model. The test (VMR
assessment) was performed on day 14 after DNBS injection. As
shown in Figure 3C, PD173212 (0.0017-1.7 mmol·kg21, i.p.)
dose-dependently reduced the visceral hypersensitivity induced
by DNBS. The compound started to be effective at a dose of
0.017 mmol·kg21 and completely relieved abdominal pain when
administered at a ten-fold higher dose (Fig. 2C).
3.3. Comparison between the effects of MRS5980 and
linaclotide in male and female rats
The effects of MRS5980 against the postinflammatory hypersen-
sitivity induced by DNBS were evaluated in both male and female
rats and compared with the effects of linaclotide, a guanylate
cyclase-C (GC-C) agonist that represents the reference drug in
the management of pain in patients affected by IBS with
predominant constipation (IBS-C).18,97 On day 14, 0.2 and
0.066 nmol kg21 linaclotide strongly reduced the VMR to CRD in
male DNBS-treated animals, whereas the ten-fold lower dose
was ineffective (Fig. 2D).
Similar to males, 14 days after DNBS injection in female rats,
both VMR and AWR to colorectal distension were significantly
higher in comparison to controls (Figs. 3A andB). The increase of
visceral sensitivity was even more pronounced in females than in
males as DNBS-treated females showed a significantly increased
response also when stimulated with the 0.5 mL volume of
distension in both the test performed (Figs. 3A and B). The acute
i.p. administration of MRS5980 dose-dependently reduced
visceral hyperalgesia induced by DNBS in female rats. In
particular, the highest doses (1.2 and 2.4 mmol·kg21) reversed
visceral sensitivity alteration back to the value of controls in
both VMR and AWR tests (Figs. 3A and B), showing similar
efficacy to linaclotide (0.2 nmol·kg21, Fig. 3A). The lowest
dose of MRS5980 (0.3 mmol·kg21) was ineffective in females
like in males (Figs. 3A and B). To note, tests were performed
in female animals synchronized for the estrous cycle choosing
the proestrous/estrous phases to eliminate any possible
confounding factor in the evaluation of A3 receptor agonists’
activity.
3.4. MRS5980 reduces persistent visceral pain
This type of pain has the peculiar tendency to become chronic in
patients remitting froman intestinal damage.84,85 Unlike VMR, the
Figure 1.Effect ofMRS5980 on postinflammatory visceral pain induced byDNBS. Effect ofMRS5980 (0.3, 1.2, and 2.4mmol·kg21; i.p.) on visceromotor response
(VMR) to CRD (left column) and abdominal withdrawal reflex (right column) on day 14 (A and B) and day 21 (C and D) after DNBS-induced colonic inflammation.
Each value is the mean 6 SEM of 6 rats per group. ^^P, 0.01 vs vehicle-treated normal controls (blue). *P , 0.05 and **P, 0.01 vs DNBS 1 vehicle-treated
group (red). CRD, colorectal distension.
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assessment of AWR allows the evaluation of DNBS-induced
hypersensitivity for a long time permitting the measurement of
persistent pain. The behavioural response was still altered 28
and 35 days after the colonic irritation (Figs. 4A and B,
respectively). Hence, we used this test to evaluate the effect of
MRS5980 on visceral pain in a more delayed phase after the
initial insult. On Day 28 and 35, the pain-relieving effect of
MRS5980 (0.3, 1.2, and 2.4 mmol·kg21) was as potent as that
seen earlier. The effect on chronic hypersensitivity was dose-
dependent, and the highest dose (2.4 mmol·kg21) was again
able to reverse the pain threshold of DNBS-treated animals to
the value of controls (Figs. 4A and B).
3.5. MRS5980 does not impair gastrointestinal transit
To determine whether the A3AR agonist MRS5980 influenced gut
motility, we assessed total gastrointestinal transit. Groups of 6 rats
were treated with either vehicle (5% DMSO) or MRS5980
(2.4 mmol·kg21). Fifteen min later, animals received an oral gavage
of 70 kDa FITC dextran (5 mg/mL, 300 mL per rat). Samples were
harvested 40 min after 70 kDa FITC-dextran administration. Total
fluorescence of 70 kDaFITC-dextranwasdetermined for eachof the
10 segments (Fig. 5A). 70 kDa FITCwas detected in vehicle-treated
samples in segments 5 (8.962.5mg/mL), 6 (3.062.2mg/mL), and
8 (6.36 3.2 mg/mL). MRS5980 treatment showed a similar pattern
of GI transit of 70 kDa FITC; segment 5:11.17 6 5.0 mg/mL,
Figure 2. Evaluation of the role of adenosine A3ARs and N-type voltage-gated calcium channels in visceral pain relief and comparison with the effect of reference
drugs. Tests were performed 14 days after DNBS treatment by measuring the visceromotor response (VMR) to colorectal distension (CRD) after compound
administration. (A) Effect of pretreatment with the selective A3 antagonist MRS1523 (5 mmol·kg
21 i.p.) on the visceral pain-relieving effect of the highly selective
A3AR agonist, MRS5980 (5mmol kg
21 i.p.). (B) Effect of the selective A3 agonist, Cl-IB-MECA (0.03, 0.3, and 2.4mmol·kg
21; i.p.). (C) Effect of the selective N-type
voltage-gated calcium channel (Cav2.2) blocker, PD173212 (0.0017-1.7 mmol·kg
21 i.p.). (D) Effect of linaclotide (0.0066-0.2 nmol·kg21 p.o.). Each value is the
mean6SEMof 6 rats per group. ^^P, 0.01 vs vehicle-treated normal controls (blue). *P, 0.05 and **P, 0.01 vsDNBS1 vehicle-treated group (red). ˚˚P, 0.01
vs DNBS 1 MRS5980 (2.4 mmol·kg21, black triangles in A) or Cl-IB-MECA (1.2 mmol kg21, black triangles in B).
Figure 3. Effect of MRS5980 and linaclotide on visceral pain induced by DNBS in female rats. Effect of MRS5980 (0.3, 1.2, and 2.4mmol·kg21; i.p.) and linaclotide
(0.2 nmol·kg21 p.o.) on visceromotor response (VMR, A) to CRD on day 14 after DNBS injection. Effect of MRS5980 (0.3, 1.2, and 2.4 mmol·kg21; i.p.) on
abdominal withdrawal reflex (AWR, B) to CRD on day 14 after DNBS injection. Each value is the mean6 SEM of 6 rats per group. ^^P, 0.01 vs vehicle-treated
normal controls (violet). *P , 0.05 and **P , 0.01 vs DNBS 1 vehicle-treated group (red). CRD, colorectal distension.
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segment 6: 11.26 6.3mg/mL, and segment 8:15.16 14.3mg/mL.
Detection of 70 kDa FITC-dextran in all other segments was
,4 mg/mL (2.1-3.7 mg/mL). No significant difference between
treatments (P 5 0.453) or the interaction of treatment and GI
segment (F(9,92) 5 P 5 0.8676) was found. FITC levels were
significantly different between the GI segments (P 5 0.0010)
indicative of intestinal movement as anticipated. These data indicate
that A3AR agonism with MRS5980 does not statistically reduce GI
transit as compared to vehicle.
To determine whether MRS5980 influenced paracellular uptake
of 70 kDa from the GI tract, we measured fluorescence in serum
collected from the same animals (Fig. 5B). Serum levels of 70 kDa
FITC-dextran were minimal (vehicle:0.82 6 0.27; MRS5980:1.38
6 0.57) and not significantly different (P 5 0.3955). These data
suggest that MRS5980 does not influence the paracellular integrity
of GI epithelium alone as compared to vehicle.
3.6. A3R agonists inhibit N-type voltage-gatedCa
21 channels
in dorsal root ganglia neurons isolated from control or
DNBS-treated rats
To gain insight into mechanisms underlying the antihyperalgesic
role of A3ARs, we explored electrophysiological properties and
Cl-IB-MECA effects in DRG primary sensory neurons isolated
from vehicle-treated (control group) or DNBS-treated rats (14
days after treatment). Concerning passive membrane properties
(Fig. 6A), DNBS neurons presented a more depolarized Vm in
comparison to those from the vehicle-treated animals (Fig. 6A,
left panel: from261.46 2.2mV in vehicle-treated to252.06 2.6
mV in DNBS group, n5 23 and n5 33, respectively, P5 0.0143,
unpaired Student t test), whereas no obvious differences were
found in Rmor Cm (Fig. 6A, central and right panels). Cmwas, on
average, 27.66 4.1 pF in vehicle-treated animals and 28.36 2.7
pF in DNBS-treated animals (Fig. 6A, right panel), corresponding
to a cell diameter of 29.9 and 30.7 mm, respectively, thus
confirming that present data were collected from small–medium-
sized DRG neurons. Of note, VDCCs, activated by a depolarizing
voltage step protocol (from250 to150mV, 200ms: see insert in
Fig. 6B), showed some differences in DNBS-treated vs vehicle-
treated rats. Although if total peak currents were unchanged,
either in amplitude (Fig. 6C) or time to peak (Fig. 6D), Ca21
currents measured at the steady state in DNBS neurons were
significantly smaller in amplitude (Fig. 6E right panel: from221.5
6 8.1 pA/pF in vehicle-treated to 21.4 6 4.0 pA/pF in DNBS
group, n 5 15 and n 5 14, respectively, P 5 0.0393, unpaired
Student t test).
Consistent with our previous work19 and with the above in vivo
results (Fig. 2), we confirmed that Cl-IB-MECA (30 nM) inhibited
Ca21 currents in DRG neurons isolated either from vehicle- or
DNBS-treated rats (Figs. 7A andB) and the effect was prevented
Figure 4. Effect of MRS5980 on persistent visceral pain induced by DNBS injection. Effect of MRS5980 (0.3, 1.2, and 2.4 mmol kg21; i.p.) was observed 28 days
(A) and 35 days (B) after DNBS treatment. The compoundwas administered 15minutes before the first colorectal distension (CRD). Visceral pain was assessed by
measuring the animal abdominal withdrawal reflex (AWR) to CRD. Each value is the mean 6 SEM of 6 rats per group. ^^P , 0.01 vs vehicle-treated normal
controls (blue). *P , 0.05 and **P , 0.01 vs DNBS 1 vehicle-treated group (red).
Figure 5. Gastrointestinal transit is not reduced by acute A3AR agonism with MRS5980. (A) Amount of 70 kDA FITC-dextran in small intestine segments 15
minutes afterMRS5980 or vehicle dosing and 40minutes after oral gavage of themarker. Two-way ANOVA, interaction: F(9,92)5 0.8676;P5 0.9553; GI Section:
P5 0.0010; Treatment: P 5 0.4584 (B) Amount of 70,000 kDa FITC-dextran in serum samples of 15 minutes after MRS5980 or vehicle dosing and 40 minutes
after oral gavage of the marker (unpaired t test, P 5 0.3955 MRS5980 compared to vehicle.) Each value is the mean 6 S.E.M. of 6 rats. ANOVA, analysis of
variance.
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by the A3AR antagonist MRS1523 (100 nM: Fig. 7B) and by the
N-type Ca21 channel blocker PD173232 (1 mM: Figs. 7C–E). No
differences were found in the percentage of Cl-IB-MECA-
inhibited Ca21 current in neurons isolated from vehicle- or
DNBS-treated rats (20.06 4.1%and 22.56 6.1%of ICa inhibition
in Cl-IB-MECA, respectively, n 5 7 in both groups; P 5 0.7332
unpaired Student t test; Fig. 7C) nor in the percentage of
PD173232-blocked currents (72.3 6 4.8% and 77.7 6 8.2%, of
ICa inhibition in PD173232, respectively; n5 4 in both groups;P5
0.5867 unpaired Student t test, data not shown). Similar
results to those obtained with the prototypical A3AR agonist
Cl-IB-MECA were recorded with MRS5980 (30 nM): the
compound inhibited, to a similar extent, Ca21 currents either
in neurons isolated from vehicle- or DNBS-treated rats and the
effect was prevented by MRS1523 and by the N-type channel
blocker PD173232 (1 mM: Figs. 7C–E).
4. Discussion
In the present work, we studied the role of A3AR as a possible new
pharmacological target for relieving visceral pain. The novel highly
selective second-generation A3AR agonist, MRS5980, as well as
the first-generation A3AR agonist, Cl-IB-MECA, were effective
against postinflammatory visceral hypersensitivity in rats. The
intracolonic injection of DNBS in rodents induces a long-lasting
visceral hypersensitivity,1,32,33 which can be measured with high
reproducibility as a lowered sensory threshold to CRD.52,61,82
DNBS-induced visceral hypersensitivity persists after the resolu-
tion of the acute inflammatory phase,1,40,53 making this model
suitable to investigate visceral pain related not only related to IBD
but also to IBS, a chronic disease characterized by a marked
abdominal pain in the absence of histopathological
explanations.84,90
The administration of A3AR agonists in the model of post-
inflammatory visceral pain showed an efficacy equivalent to that
of linaclotide, an approved treatment for reducing abdominal pain
(and also abdominal bloating and bowel symptoms) in adult
patients suffering from IBS with predominant constipation (IBS-
C).13,18
The efficacy of MRS5980 and linaclotide was confirmed in
female rats. These data have a clinical significance because IBS
affects more women than men.12 Abundant evidence from
Figure 6. Electrophysiological properties of DRG neurons isolated from vehicle- or DNBS-treated rats. (A) Pooled data (mean 6 SEM) of passive membrane
properties (restingmembrane potential: Vm, left panel; membrane resistance: Rm, central panel, and cell capacitance: Cm, right panel) measured in DRG neurons
isolated from vehicle- (veh) or DBNS-treated rats (DNBS). Unpaired Student t test, n 5 23 and n 5 33, respectively. (B) Original Ca21 current traces elicited in
representative DRG neurons isolated from a vehicle- (black traces) or DNBS-treated (red traces) rat by applying a depolarizing voltage step protocol (from250 to
150mV, 200ms duration, Vh5265mV: see inset). Averaged I-V plots of peak Ca21 currents (C), and pooled data of time to peak of Ca21 currents (D), measured
at different step potentials in 17 cells isolated from vehicle-treated rats and 15 cells isolated from DNBS-treated animals. No significant differences were found
between groups at any step potential, unpaired Student t test. (E) Left panel: averaged I-V plot of steady-state Ca21 currents measured in 17 cells isolated from
vehicle-treated rats and 15 cells isolated from DNBS-treated animals. Right panel: pooled data of the same currents measured at the 0 mV step. (A) significant
reduction of steady-state Ca21 currents was found in the DNBS-treated group, P 5 0.0393, unpaired Student t test. DRG, dorsal root ganglia.
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epidemiologic studies clearly demonstrates that women are at
substantially greater risk for many clinical pain conditions.5 In
accordance, the present results showed a higher visceral
hypersensitivity in female animals than in males. This phenom-
enon is not limited to abdominal/pelvic pain (such as IBS, painful
bladder syndrome, and dyspareunia), but also includes con-
ditions associated with neuropathic pain, musculoskeletal pain,
orofacial pain, and headache/migraine.27 Women are therefore
more likely than men to pursue a variety of treatments for many
painful conditions.
The trinitrobenzenesulfonic acid (TNBS)-induced model was
used in preclinical studies to identify the potential clinical utility of
linaclotide.25 Our results with linaclotide in the DNBS-induced
model support previous findings. The analgesic mechanism of
linaclotide involves the activation of guanylate cyclase-C (GC-C)
expressed on mucosal epithelial cells, resulting in the production
and release of cyclic guanosine-39,59-monophosphate (cGMP).
The extracellular cGMP acts on and inhibits nociceptors, thereby
reducing nociception.13 Although linaclotide is an efficacious,
well-tolerated treatment option for improving both bowel
symptoms and abdominal pain in IBS-C, it acts as a secreta-
gogues and this implies that most patients reported episodes of
diarrhea within the first 2 to 4 weeks of treatment.18 This adverse
effect also makes linaclotide unsuitable for patients affected by
diarrhoea-predominant IBS or IBS with alternating constipation
and diarrhoea. In healthy condition, adenosinemodulated colonic
cholinergic motility through activation of A3 receptors in the
myenteric plexus. Antonioli et al. demonstrated that A3 receptor-
mediated tonic inhibitory control by adenosine was impaired in
inflamed bowel, despite the increased density of functioning and
pharmacologically recruitable A3 receptors found in the gut.
2 To
verify a possible interaction of MRS5980 with gut motility, we
performed focused experiments. Our findings using 70 kDa FITC-
dextran revealed that MRS5980 does not impair gastrointestinal
transit as compared to vehicle. Importantly, these results indicate
that the antihyperalgesic efficacy of MRS5980 in visceral pain
condition is not associated to motility alteration, suggesting
a mechanism related to sensitivity modulation rather than
spasmolytic activity. This profile is different, eg, from the opioid
analgesic drugs, mainly used in patients affected by IBS-D, that in
the same experiment reduce intestinal transit leading to
constipation in humans.10,47,66,76 Anyway, the impact of A3
receptor agonists’ repeated administrations on intestinal motility
and sensitivity is an aspect that needs to be explored further in the
perspective of developing these molecules as drugs and of
establishing a therapeutic regime in patients. The lack of
significant long-term effects on intestinal motility could privilege
A3 adenosine agonists over all the other drugs currently in use.
Anyway, in clinical trials investigating the efficacy of A3 receptor
agonist on rheumatoid arthritis and psoriasis, no relevant
gastrointestinal side effects were reported.20,41,80The efficacy of
A3AR agonists against visceral pain is consistent with data
showing that the A3AR is involved with multiple pain mechanisms
at peripheral, spinal, and supraspinal levels.43,50 There is
evidence that A3AR agonists are antihyperalgesic against
neuropathic pain through inhibition of the astrocyte-associated
neuroinflammatory response in the spinal cord,42,44,96 a phenom-
enon strongly involved in pain persistence.22,23 A3AR activation
has been reported to enhance the formation of anti-inflammatory
cytokines36,42,44,96 and the production of glial-derived neuro-
protective substances.99 Furthermore, in vitro and in vivo studies
demonstrate that A3AR produces its effects by inhibiting the p38
MAPK and NF-kB signaling pathways42,55,92,94 and inflamma-
some activity.96 All these mechanismsmay contribute to the relief
Figure 7. Effects of the adenosine A3R agonists Cl-IB-MECA and MRS5950 on voltage-gated Ca
21 currents in isolated DRG neurons. (A) Time course (left panel)
and representative Ca21 current traces (right panel) measured in a representative DRG neuron isolated from a DNBS-treated rat (DNBS) before and after the
application of the A3R agonist Cl-IB-MECA (30 nM) or the Ca
21 channel blocker Cd21 (100 mM). (B) Averaged time courses of peak Ca21 currents during Cl-IB-
MECA (30 nM) superfusion in vehicle-treated or DNBS-treated animals in the absence or presence of the A3AR antagonist, MRS1523 (1523: 100 nM). Pooled data
(mean6SEM) of%Ca21 current inhibition induced by Cl-IB-MECA (C) orMRS5980 (D) applied alone or in combinationwithMRS1523 or PD173232 (PD; 1mM) in
vehicle-treated (white columns) or DNBS-treated (red columns) animals. In all panels: *P ,0.05 vs respective control, paired Student t test. (E) Averaged time
course of peak Ca21 currents before or after MRS5980 (30 nM) superfusion DNBS rats in the presence of the A3AR antagonist MRS1523 or the Ca
21 channel
blocker PD173232 (1 mM). DRG, dorsal root ganglia.
Copyright © 2020 by the International Association for the Study of Pain. Unauthorized reproduction of this article is prohibited.
2186 E. Lucarini et al.·161 (2020) 2179–2190 PAIN®
of colitis-evoked visceral pain consistently with the reports that
A3AR activation reduced colitis-induced tissue injury by modu-
lating theNF-kB signalling pathway and through inhibiting NLRP3
inflammasome activation and pyroptosis in human colonic
epithelial cells.70,71
A3ARs may limit excitatory neurotransmission, which is altered
in chronic34 as well as in visceral pain.31,48,98 For example, the
protective role of A3AR in the first phase of ischemia seems to be
at least partly related to a decrease in synaptic transmis-
sion.67,68,72 Moreover, A3AR activation protects against the
neurotoxic intracellular Ca21 rise mediated by P2X7 or NMDA
receptors.103,104 All the mechanisms described above could
account for a therapeutic effect of repeated administrations of A3
receptor agonists, which is another aspect interesting to study.
Anyway, the acute efficacy showed by A3 receptor agonists in
reducing visceral hypersensitivity can be only partially explained
by the mechanisms of action previously cited. This consideration
has aroused our interest in elucidating further the pharmacody-
namic mechanisms of A3 receptor agonists on pain.
As recently demonstrated,19 selective A3AR stimulation inhibits
N-type Cav2.2 opening in isolated rat DRG neurons. Here, we
found that both Cl-IB-MECA and MRS5980 significantly inhibited
Cav2.2 activation in DRG neurons of DNBS-treated rats. The
effect was prevented by the selective A3AR antagonist,
MRS1523, and by the Cav2.2 blocker, PD173212, confirming
the involvement of Cav2.2 in the A3AR-mediated effect. We did
not measure a significant difference between A3AR-mediated
inhibition in DRG neurons isolated from DNBS-treated vs vehicle-
treated animals. However, alterations in passive membrane
properties and steady-state Ca21 currents were observed
between the 2 groups. The resting membrane potential was
significantly more depolarized in DRG neurons isolated from
DNBS-treated animals, suggesting a hyperexcitable state. In-
terestingly, steady-state Ca21 currents, but not peak Ca21
currents, were markedly reduced in DRG neurons isolated from
DNBS animals. In an attempt to explain the relationship between
steady-state Ca21 current reduction in DRG neurons and visceral
hypersensitivity, we hypothesize that a decrease in sustained
Ca21 influx into the cell can lead to membrane potential instability
and depolarization through a decrease of Ca21-activated K1
channel (KCa) opening. Ca
21-activated K1 channel is known to
stabilize the membrane potential and participate in repolarizing
neurons after action potential firing, thus avoiding bursting
activity.37,63,102
Moreover, a recent publication demonstrates that Cav2.2
induces a voltage-dependent, but Ca21-independent ATP
secretion from the soma of DRG neurons.15 ATP is a powerful
mediator of pain, for example, ATP-induced P2X3 receptor
activation is involved in visceral pain, as shown by the ability of
P2X3 antagonist A-317491 to potently reduce hypersensitivity.21
The hypothesis that Cav2.2-mediated modulation contributes
to A3AR-mediated antihyperalgesia is supported by other
evidence. Modulation of Cav2.2 channel activity is implied in the
pharmacodynamics of pain-relieving compounds, such as other
Gi-coupled receptor agonists, eg, opioids, cannabinoids, neuro-
peptide Y, and substance P.7,78,81,87,91 Also, the neuropathic
pain analgesics gabapentin and pregabalin28 inhibit Cav2.2-
mediated synaptic transmission.6,88 Gabapentinoids are effective
in reducing visceral pain and preventing spinal neuronal activation
associated with CRD in animals62,69,79 and have been suggested
to be treatments for IBS.11 A direct inhibitor of Cav2.2 channel
activity, ziconotide, is currently used clinically for pain therapy,
although it is limited to the intrathecal route.56 In our hands, the
i.p. administration of the specific Cav2.2 inhibitor
PD17321238,56,73 significantly decreased visceral hypersensitiv-
ity in DNBS-treated animals. In conclusion, A3AR agonists seem
to be a promising resource for visceral pain management, an
unmet medical need that impairs quality of life.
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